Foot mycoses –⁠ treatment with over-the-counter preparations based on clinical recommendations

Czech version

Authors: Ivana Kuklová
Authors‘ workplace: Dermatovenerologická klinika VFN v Praze
Published in: Čes. slov. Farm., 2026; 75, 122-126
Category: Self Medication
doi: https://doi.org/10.36290/csf.2026.022

Overview

Tinea pedis (athlete’s foot) is a superficial fungal skin infection caused by dermatophytes, most commonly the anthropophilic dermatophyte Trichophyton rubrum. Clinically, it is characterized mainly by scaling, erythema, and fissure formation, and it may present in three primary forms: interdigital, plantar, and vesiculobullous. The infection is often accompanied by mild pruritus; when fissures develop, burning and pain may also occur.

Maceration, fissures, and desquamation of the stratum corneum in the interdigital spaces may serve as entry points for β-haemolytic streptococci, thereby increasing the risk of erysipelas. Another complication is the potential spread of infection to the nails, hands, groin, or other body sites.

Tinea pedis is primarily indicated for topical antifungal therapy. Over-the-counter antifungal agents include imidazoles, allylamines, thiocarbamates, and undecylenic acid derivatives. Based on an analysis of clinical studies, their efficacy and duration of treatment have been compared.

Keywords:

Trichophyton rubrum – dermatophytes – treatment – tinea pedis – allylamines – imidazoles

Sources

1. Martinez-Rossi NM, Peres NTA, Bitencourt TA, et al. State-of-the-art dermatophyte infections: epidemiological aspects, pathophysiology, and resistance mechanisms. J Fungi (Basel). 2021;7(8):629.

2. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995;8(2):240-259.

3. Yazdanpanah S, Sasanipoor F, Khodadadi H, et al. Quantitative analysis of in vitro biofilm formation by clinical isolates of dermatophyte and antibiofilm activity of common antifungal drugs. Int J Dermatol. 2023;62(1):120-127.

4. Mercer DK, Stewart CS. Keratin hydrolysis by dermatophytes. Med Mycol. 2019;57(1):13-22.

5. Nenoff P, Krüger C, Ginter-Hanselmayer G, Tietz HJ. Mycology –⁠ an update. Part 1: dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges. 2014;12(3):188-209.

6. Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2015;41(3):374-388.

7. Zhan P, Liu W. The changing face of dermatophytic infections worldwide. Mycopathologia. 2017;182(1–2):77-86.

8. Aste N, Pau M, Aste N, et al. Tinea pedis observed in Cagliari, Italy, between 1996 and 2000. Mycoses. 2003;46(1–2):38-41.

9. Cheng S, Chong L. A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong. Chin Med J (Engl). 2002;115(6):860-865.

10. Leibovici V, Evron R, Dunchin M, et al. Population-based epidemiologic study of tinea pedis in Israeli children. Pediatr Infect Dis J. 2002;21(9):851-854.

11. Gentles JC, Evans EG. Foot infections in swimming baths. Br Med J. 1973;3(5874):260-262.

12. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591-1594.

13. Sobera JO, Elewski BE. Fungal diseases. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 2nd ed. Elsevier; 2018 : 1135-62.

14. Státní ústav pro kontrolu léčiv. Databáze léčivých přípravků –⁠ antimykotika k lokálnímu použití (volně prodejné léčivé přípravky). Praha: SÚKL; [cit. 2026-05-11]. Dostupné z: https://www.sukl.cz

15. Poojary SA. Topical antifungals: a review and their role in current management of dermatophytoses. Clin Dermatol Rev. 2017;1(Suppl 1):S24-S29.

16. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2008;(2):CD001434.

17. Korting HC, Tietz HJ, Bräutigam M, et al. One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. Med Mycol. 2001;39(4):335-340.

18. James IG, Loria-Kanza Y, Jones TC. Short-duration topical treatment of tinea pedis using terbinafine emulsion gel: results of a dose-ranging clinical trial. J Dermatolog Treat. 2007;18(3):163-168.

19. Ortonne JP, Korting HC, Viguié-Vallanet C, et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol. 2006;20(10):1307-1313.

20. Rotta I, Ziegelmann PK, Otuki MF et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149(3):341-349.

21. Sinha SD, Rajamma A, Bandi MR, et al. Efficacy and safety of naftifine hydrochloride 2% gel in interdigital tinea pedis: a phase III randomized, double-blind, parallel-group, active-controlled study in Indian adult patients. Clin Drug Investig. 2023;43(6):565-574.

22. Meinhof W, Girardi RM, Stracke A. Patient noncompliance in dermatomycosis: results of a survey among dermatologists and general practitioners and patients. Dermatologica. 1984;169(Suppl 1):57-66.